Document Detail


Current therapy for dysgerminoma of the ovary.
MedLine Citation:
PMID:  3299187     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
It is important that therapy of ovarian dysgerminoma be optimized because of the young age of women affected and the threat that therapy may pose to fertility. Our understanding of dysgerminoma has improved, so that treatment schemes with better therapeutic ratio may now be used. Approximately 65% of patients present with stage IA disease. For those wishing to preserve fertility, conservative surgery with close clinical, radiologic, and serologic follow-up is the treatment of choice, with chemotherapy for relapse. Cure rates should approach 100%, and fertility is usually preserved. Intra-abdominal relapse in those not wishing to preserve fertility should be treated with modest-dose pelvic and abdominal irradiation. For those patients with disease presenting in stages IB, II, and III who wish to maintain fertility, unilateral oophorectomy followed by combination chemotherapy may be curative and spare ovarian function. Otherwise, complete surgery, followed by abdominopelvic radiation therapy, is recommended. This treatment produces less morbidity than chemotherapy and will cure approximately two-thirds of patients. Chemotherapy should be used for salvage of subsequent relapse. Both radiation and chemotherapy are highly effective treatment modalities for dysgerminoma. This information, coupled with better understanding of the patterns of disease spread and improved ability to identify nondysgerminomatous elements using serum tumor markers, means that a more conservative approach can be taken to management without compromising the chance of cure. Cure rates for dysgerminoma should now approach the role of 97% achieved in the comparable tumor, testicular seminoma.
Authors:
G M Thomas; A J Dembo; N F Hacker; A D DePetrillo
Related Documents :
3139507 - Ten years experience with a chemotherapy regime for ovarian cancer.
19922987 - Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
22253617 - Identification of regional lymph node involvement of colorectal cancer by serum seldi p...
21540757 - The importance of scatter correction for the assessment of lung shunting prior to yttri...
8032707 - Control of emesis by intravenous granisetron in breast cancer patients treated with 5-f...
18495007 - Exophytic growth of a neglected giant subcutaneous leiomyosarcoma of the lower extremit...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  70     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  1987 Aug 
Date Detail:
Created Date:  1987-08-19     Completed Date:  1987-08-19     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  268-75     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Combined Modality Therapy
Dysgerminoma / pathology,  therapy*
Female
Humans
Neoplasm Recurrence, Local / therapy
Neoplasm Staging
Ovarian Neoplasms / pathology,  therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Normal fetal heart axis and position.
Next Document:  Pseudophakic keratoplasty: posterior chamber lens implantation in the presence of ruptured capsule.